Efficacy and safety of nafamostat mesylate versus heparin anticoagulation in adult kidney disease patients using continuous renal replacement therapy: a systematic review and meta-analysis.

Yao Wang, Qiuhong He, Dan Wen, Rong Xu, Xiao Yu, Lingning Zhao

Abstract readSystematic Review

In one paragraph

Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Implementation quality as a modifiable determinant of filter lifespan in regional citrate anticoagulation: a real-world clustering-adjusted study.Renal failure · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yao Wang *Intensive Care Unit, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Qiuhong He *Intensive Care Unit, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Dan WenIntensive Care Unit, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Rong XuIntensive Care Unit, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Xiao YuIntensive Care Unit, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Lingning ZhaoIntensive Care Unit, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anticoagulation is essential during continuous renal replacement therapy (CRRT) for acute kidney injury to maintain circuit patency and balance bleeding risks. Objective: Systematically compare the anticoagulant efficacy and safety of nafamostat mesylate (NM) versus heparin in CRRT. Methods: We searched China National Knowledge Infrastructure, Wanfang Database, China Biology Medicine, PubMed, Embase, Cochrane Library, and Web of Science up to June 30, 2025 for randomized or non-randomized controlled trials. A meta-analysis was performed using RevMan version 5.4 software. Results: Seven retrospective cohort studies comprising were included. No significant differences between the two groups regarding filter lifespan [MD = -1.05; 95% CI (-5.92, 3.83); Conclusion: NM demonstrates similar filter lifespan and bleeding safety to heparin in CRRT. NM may shorten hospital stay and differentially affects coagulation indicators, supporting its use in individualized anticoagulation. But because of poor evidence, the conclusions must be interpreted with caution. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251077749.

Indexed as

anticoagulationcontinuous renal replacement therapyheparinmeta-analysisnafamostat mesylate

Identifiers

PMID41783064

DOI10.3389/fmed.2026.1713412

PMCPMC12953472

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.